Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
4 p, 551.6 KB Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype / Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Tuechler, Heinz (Boltzmann Institute for Leukaemia Research and Hematology) ; Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ; Raynaud, Sophie (Cote d'Azur University) ; Cluzeau, Thomas (Cote d'Azur University) ; Shih, Lee-Yung (Chang Gung University) ; Tung-Liang, Chiang (Chang Gung University) ; Ganster, Christina (University Medical Center Göttingen) ; Shirneshan, Katayoon (University Medical Center Göttingen) ; Haase, Detlef (University Medical Center Göttingen) ; Mascaró, Martí (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Palomo Sanchís, Laura (Vall d'Hebron Institut d'Oncologia) ; Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ; Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ; Trim, Nicola (Birmingham Women's Hospital) ; Jeffries, Sally (Birmingham Women's Hospital) ; Ridgway, Emma (Birmingham Women's Hospital) ; Marconi, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ; Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. [...]
2023 - 10.1002/jha2.651
EJHaem, Vol. 4 (february 2023) , p. 446-449  
2.
15 p, 3.4 MB Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS / Kuendgen, A. (University Hospital Duesseldorf) ; Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tuechler, H. (Boltzmann Institute for Leukemia Research. Hanusch Hospital) ; Garcia-Manero, Guillermo (MD Anderson Cancer Center) ; Komrokji, R. S. (H Lee Moffitt Cancer Center) ; Sekeres, M. A. (Taussig Cancer Institute. Cleveland Clinic) ; Della Porta, M. G. (Humanitas Research Hospital (Itàlia)) ; Cazzola, Mario (IRCCS Policlinico San Matteo Foundation) ; DeZern, A. E. (Johns Hopkins University. Sidney Kimmel Comprehensive Cancer Center) ; Roboz, G. J. (Weill Cornell Medicine and The New York Presbyterian Hospital) ; Steensma, D. P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Van de Loosdrecht, A. A. (Vrije Universiteit Amsterdam) ; Schlenk, R. F. (Heidelberg University Hospital (Alemanya)) ; Grau, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Blum, S. (Lausanne University Hospital) ; Pereira, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Valent, P. (Medical University of Vienna) ; Costa, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Giagounidis, A. (Marienhospital Duesseldorf) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Döhner, H. (University Hospital of Ulm (Alemanya)) ; Platzbecker, Uwe (University Hospital Leipzig) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Lübbert, M. (University Medical Center Freiburg) ; Oiartzabal, I. (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ; Díez-Campelo, M. (Hospital Universitario de Salamanca) ; Cedena, María Teresa (Hospital Universitario 12 de Octubre (Madrid)) ; Machherndl-Spandl, S. (St Vincent's Hospital (Sydney)) ; López-Pavía, M. (Hospital General Universitario de Valencia) ; Baldus, C. D. (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Martinez-de-Sola, M. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Stauder, R. (Innsbruck Medical University) ; Merchan, B. (Hospital Universitari Vall d'Hebron) ; List, A. (H Lee Moffitt Cancer Center) ; Ganster, Christina (University Medical Center Göttingen) ; Schroeder, T. (University Hospital Duesseldorf) ; Voso, Maria Teresa (Tor Vergata University. Department of Biomedicine and Prevention) ; Pfeilstöcker, M. (Hanusch Krankenhaus Wien) ; Sill, H. (Medizinische Universität Graz) ; Hildebrandt, B. (University Duesseldorf. Institute of Human Genetics) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Nomdedeu, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cobo, Fernando (Hospital Quirón Teknon) ; Haas, R. (University Hospital Duesseldorf) ; Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Germing, U. (University Hospital Duesseldorf) ; Greenberg, P. L. (Stanford University Cancer Center) ; Haase, Detlef (University Medical Center Göttingen) ; Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ; Universitat Autònoma de Barcelona
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. [...]
2020 - 10.1038/s41375-020-0917-7
Leukemia, 2020  

Vea también: autores con nombres similares
1 Tuechler, Heinz
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.